Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial
- 1 July 2004
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 364 (9428), 29-34
- https://doi.org/10.1016/s0140-6736(04)16586-0
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Comparison of Generic Zidovudine + Lamivudine (Cipla, Duovir) and the GlaxoSmithKline Brand (Combivir) TabletsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- The safety, tolerability and effectiveness of generic antiretroviral drug regimens for HIV-infected patients in south IndiaAIDS, 2003
- Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapyAIDS, 2003
- Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in SenegalAIDS, 2003
- Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stageVirology, 2003
- Adherence to HAART RegimensAIDS Patient Care and STDs, 2003
- News from the 10th Conference on Retroviruses and Opportunistic InfectionsInpharma Weekly, 2003
- Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1998
- High-performance liquid chromatographic assay for 2′-deoxy-3′-thiacytidine in human serumJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Determination of stavudine, a new antiretroviral agent, in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detectionJournal of Chromatography B: Biomedical Sciences and Applications, 1992